Condition: Diffuse Large B-Cell Lymphoma · Sponsor: Ruijin Hospital
The purpose of this study is to compare the efficacy and safety of genotype-guided targeted agents in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola RCHP-X) versus Pola RCHP in Chinese patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
This description comes directly from the study's public registry record.
Weili Zhao · +862164370045 · zwl_trial@163.com
Pengpeng Xu · +862164370045 · pengpeng_xu@126.com
Always discuss trial participation with your own doctor first.
| Ruijin Hospital, Shanghai JiaoTong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06803693